Stockscreener 앱 받기
66.53
0.15%
0.10
Biomarin Pharmaceutical Inc 주식(BMRN)의 최신 뉴스
Weekly Buzz: RARE, REGN Secure FDA Nod, BMRN Stikes Deal; HUMA, EYPT Face Trial Setbacks - RTTNews
NFJ Investment Group LLC Takes Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
40,919 Shares in BioMarin Pharmaceutical Inc. $BMRN Bought by Paralel Advisors LLC - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Raised to "Strong-Buy" at BMO Capital Markets - MarketBeat
Eagle Health Investments LP Acquires Shares of 624,676 BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Edmond DE Rothschild Holding S.A. Purchases Shares of 687,030 BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Boehringer again rises up rare disease reputation rankings - Fierce Pharma
Why BioMarin Pharmaceutical (BMRN) Stock Is Up Today - Yahoo Finance
BioMarin Pharmaceutical (BMRN)’s Alesta Deal Adds New Growth Potential in Rare Diseases - Yahoo Finance
BMRN Looks 16.4% Undervalued on GF Value™ Amid Market Concerns Over Voxzogo - GuruFocus
BioMarin initiated an outperform at BMO as Voxzogo erosion overstated - Seeking Alpha
BioMarin Pharmaceutical Market Sentiment - Benzinga France
BioMarin Inks $490M Deal to Buy Rare Bone Disease Treatment - Zacks Investment Research
BIOMARIN PHARMACEUTICAL INC. : BMO INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $98 - Bitget
Canaccord reiterates BioMarin stock rating on Alesta acquisition By Investing.com - Investing.com South Africa
H.C. Wainwright cuts BioMarin stock price target on acquisition costs By Investing.com - Investing.com South Africa
BMO Capital Markets Initiates Coverage on BioMarin Pharmaceutical (NASDAQ:BMRN) - MarketBeat
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For We - Benzinga
BMO initiates BioMarin stock with Outperform, $98 price target By Investing.com - Investing.com South Africa
Canaccord reiterates BioMarin stock rating on Alesta acquisition - Investing.com
H.C. Wainwright cuts BioMarin stock price target on acquisition costs - Investing.com
BMRN Initiated Coverage by BMO Capital -- Rating Set at Outperform - GuruFocus
BioMarin to Acquire RTW Biotech Portfolio Company Alesta Therapeutics for Up to $490 Million - Kalkine Media
BMO initiates BioMarin stock with Outperform, $98 price target - Investing.com
BioMarin to acquire Alesta Therapeutics for up to $490 million By Investing.com - Investing.com Australia
GSA Capital Partners LLP Invests $944,000 in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Sahm
BioMarin to acquire Alesta Therapeutics for up to $490 million - Investing.com
REGRTW Biotech Opp.BioMarin to acquire Alesta Therapeutics - TradingView
BioMarin to acquire Alesta Therapeutics for $275M upfront By Investing.com - Investing.com Nigeria
BioMarin to Acquire Alesta in Cash Deal, Betting on First Oral HPP Therapy - nai500.com
BioMarin Buying Alesta Therapeutics For Up To $490M - Law360
BMRN Looks 19.4% Undervalued on GF Value™ - GuruFocus
BioMarin looks to spur growth with potential $490M buyout of Dutch bone drug company - The Business Journals
BioMarin snaps up Alesta's lead asset for $275m - pharmaphorum
BioMarin Pays $275M Upfront for Alesta to Challenge AstraZeneca in Rare Bone Disease - finance.biggo.com
BioMarin Seeks to Strengthen Market Position in Rare Bone Disease Treatment - Benzinga
BioMarin to Acquire Alesta Therapeutics for Up to $490 Million - citybiz
BioMarin acquires experimental drug for rare bone disorder in $275M deal - BioPharma Dive
BMRN Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
BioMarin stock surges on $275M Alesta acquisition deal By Investing.com - Investing.com Australia
HC Wainwright Has Lowered Expectations for BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price - MarketBeat
M&A Roundup: LEO Pharma Acquires Dersimelagon, BioMarin Acquires Alesta, OmniAb Enters collaboration with Eli Lilly, Chugai and GSK Enter License Agreement for AID351 - Pharmaceutical Executive
BioMarin stock surges on $275M Alesta acquisition deal - Investing.com
BioMarin Shares Jump After $275 Million Deal to Acquire Alesta Therapeutics - Yahoo Finance
Form 8K Biomarin Pharmaceutical Inc For: 18 August By Investing.com - Investing.com Nigeria
BioMarin bulks up bone unit with $275M Alesta buyout to challenge AstraZeneca - Fierce Biotech
BioMarin Pharmaceutical to Acquire Alesta Therapeutics for up to $490 Million - marketscreener.com
BioMarin to acquire Alesta Therapeutics for $275M upfront - Investing.com
BioMarin to acquire Alesta for $275M upfront (BMRN:NASDAQ) - Seeking Alpha
BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline - PR Newswire
Rice Hall James & Associates LLC Makes New Investment in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Grandfield & Dodd LLC Takes $1.04 Million Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BMRN Stock Rises On Up To $490M Alesta Deal, But Analyst Cuts Price Target To $59 — Here’s Why - Stocktwits
0.86%
0.31%
자본화:
|
볼륨(24시간):